SSTR2 and central nervous system cancer: Direct support to such speculation emerged from previous studies describing the role of SST-, OCT- and SSTR2-specific non-peptide agonist in regulation of cAMP, SHP2, MAPK using human U343 glioma cells that resulted in dephosphorylation of EGFR and PDGFR linked to the inhibition of ERK1/2 phosphorylation [30].